Passively transferred neutralizing antibodies (nAbs) have provided definitive protection from HIV-1 infection, yet identification and mechanistic study of these nAbs has not resulted in the development of a protective vaccine. We hypothesize that previous immunogen design efforts have achieved limited success due to their limited scope and restricted focus. The lack of a high-performance screening platform places severe constraints on immunogen design and has impeded the translation of findings from basic science into vaccine development. When attempting to elicit protective antibodies against a highly diverse virus in the context of a disease in which naturally occurring protective immune responses are largely absent, we posit that the scale of technology and methods used must be adequately matched to the scale of the task. Combinatorial, high-throughput protein engineering platforms can achieve the landscape coverage that may be necessary for successful development of a preventative HIV vaccine, and allow us to translate our understanding of nAbs into the induction of protective antibody responses. We therefore propose to develop high-performance protein engineering tools to screen billions of HIV envelope trimer sequence variants according to defined criteria, allowing us to evolve envelope immunogens tailored to effectively present functionally relevant and immunogenic epitopes capable of driving the generation of protective antibodies. The multi-pronged strategy we describe both leverages the growing reagent toolkit for traditional immunogen design, including more than a dozen new broad nAbs, and improved means to functionally parse Abs present in diverse, polyclonal samples;and further explores a complementary strategy based on selective engagement of na?ve and germline antibody repertoires which we believe addresses the fundamental limitation of previous immunogen design efforts and represents an innovative and unbiased forward engineering strategy to induce the generation of neutralizing antibodies. Ultimately, the tools developed by these studies represent adaptable platforms capable of rapidly selecting envelope variants from vast sequence diversity according to flexible design criteria, and may open a path to a fundamental breakthrough in immunogen design by bridging the translational gap that has come to be known as "the nAb problem".
Our proposed studies aim to improve our understanding of the interaction between the HIV envelope and the immune system, providing new insight into envelope-based vaccine design, facilitating development of a protective vaccine to contain the HIV epidemic.
|Bonsignori, Mattia; Wiehe, Kevin; Grimm, Sebastian K et al. (2014) An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest 124:1835-43|
|Lai, Jennifer I; Licht, Anna F; Dugast, Anne-Sophie et al. (2014) Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. J Virol 88:2799-809|
|Grimm, Sebastian K; Ackerman, Margaret E (2013) Vaccine design: emerging concepts and renewed optimism. Curr Opin Biotechnol 24:1078-88|
|Boesch, Austin W; Zhao, Yifeng; Landman, Alison S et al. (2013) A multiplexed assay to detect antimicrobial peptides in biological fluids and cell secretions. J Immunol Methods 397:71-6|